BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Melodic Event: A Survey of \Energies and Exhibitions Assessed\ Live concert - 2The most effective method to Integrate Compact disc Rates into Your Retirement Arranging
- 3Washington resident is infected with a different type of bird flu
- 4Heading to Florida for NASA's Artemis 2 moon launch? Here's what to know before you go
- 5A Colombian city swaps iconic horse buggies for electric carriages amid animal welfare concerns
- Discovery off Israel’s coast reveals earliest known 2,600-year-old shipment of raw iron
- They died 'doing what they loved': The stories of workers in their 80s who died on the job
- Moon rush: These private spacecraft will attempt lunar landings in 2026
- Inside Kathy Hilton’s Christmas pajama party: caviar bumps, champagne vending machines and a mansion full of Housewives
- Former IRGC child executioner tells ‘Post’ how he became devout Christian dissident
- Bother Control Administrations for 2024: Decide for Your Home
- The powerful new Rubin Observatory just found 11,000 new asteroids and measured 'tens of thousands more'
- Stop the ‘good’ vs ‘bad’ snap judgments and watch your world become more interesting
- Regeneron's experimental therapy combo effective in untreated cancer patients
